NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023
Kelvin A. Moses(Exelixis (United States)), Preston C. Sprenkle(Exelixis (United States)), Clinton D. Bahler(Exelixis (United States)), Geoffrey N. Box(Exelixis (United States)), Sigrid Carlsson(Memorial Sloan Kettering Cancer Center), William J. Catàlona(Exelixis (United States)), Douglas M. Dahl(Exelixis (United States)), Marc Dall’Era(Exelixis (United States)), John W. Davis(The University of Texas MD Anderson Cancer Center), Bettina F. Drake(Barnes-Jewish Hospital), Jonathan I. Epstein(Exelixis (United States)), Ruth B. Etzioni(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Thomas A. Farrington(Exelixis (United States)), Isla P. Garraway(Exelixis (United States)), David F. Jarrard(Exelixis (United States)), Eric Kauffman(Roswell Park Comprehensive Cancer Center), Deborah R. Kaye(Exelixis (United States)), Adam S. Kibel(Exelixis (United States)), Chad A. LaGrange(Exelixis (United States)), Paul Maroni(Exelixis (United States)), Lee Ponsky(Cleveland Clinic), Brian Reys(Exelixis (United States)), Simpa S. Salami(Exelixis (United States)), Alejandro Sánchez(Exelixis (United States)), Tyler M. Seibert(Exelixis (United States)), Terrence Shaneyfelt(Exelixis (United States)), Marc C. Smaldone(Fox Chase Cancer Center), Geoffrey A. Sonn(Exelixis (United States)), Mark D. Tyson(Exelixis (United States)), Neha Vapiwala(University of Pennsylvania), Robert Wake(St. Jude Children's Research Hospital), Samuel L. Washington(UCSF Helen Diller Family Comprehensive Cancer Center), Alice Yu(Moffitt Cancer Center), Bertram Yuh(City Of Hope National Medical Center), Ryan A. Berardi(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 152Open Access
Abstract
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.
Related Papers
No related papers found
Powered by citation graph analysis